SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Inc. (NASDAQ: VCYT) announced today that it will report its second
quarter 2017 financial results after the close of market on Monday, July
31, 2017. Following the announcement, Veracyte's management will host a
live conference call and webcast at 4:30 p.m. Eastern Time to discuss
the company's financial results and business progress.
The live webcast and subsequent replay may be accessed by visiting
Veracyte's website at http://investor.veracyte.com.
Alternatively, please call (855) 541-0980 (U.S.) or (970) 315-0440
(international) to listen to the live conference call. The conference ID
number is 44718214. The webcast replay will be available on the
company's website approximately two hours following completion of the
call and archived on the company's website for 90 days.
Veracyte is a leading genomic diagnostics company that is fundamentally
improving patient care by resolving diagnostic uncertainty with evidence
that is trustworthy and actionable. The company's products uniquely
combine genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward
without risky, costly surgery that is often unnecessary. Since its
founding in 2008, Veracyte has commercialized three genomic tests, which
are transforming the diagnosis of thyroid cancer, lung cancer and
idiopathic pulmonary fibrosis and collectively target a $2 billion
market opportunity. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma
logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170718005783/en/
Tracy Morris, 650-380-4413
Source: Veracyte, Inc.
News Provided by Acquire Media